Cinacalcet HC1 (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism

Clinical Nephrology

Volumn 68, Issue 1, 2007, Pages 10-17

  Sterrett, J Reid ^a,k   Strom, J ^b   Stummvoll, H K ^c   Bahner, U ^d   Disney, A ^e   Soroka, S D ^f   Corpier, C ^g   Arruda, J A ^h   Schwanauer, L E ⁱ   Klassen, P S ⁱ   Olson, K A ⁱ   Block, G A ^j  

^a ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELISABETHINEN HOSPITAL   (Austria)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f DALHOUSIE UNIVERSITY   (Canada)

^g Dallas Nephrology Associates   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ AMGEN INC   (United States)

^j Denver Nephrologists   (United States)

^k Department of Medicine ^*  (United States)

more..

Author keywords

Calcimimetic; Cinacalcet; Hemodialysis; Seconday hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; VITAMIN D; NAPHTHALENE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SEIZURE; STATISTICAL SIGNIFICANCE; VOMITING; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TIME;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS; TIME FACTORS;

EID: 34447281257     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68010     Document Type: Article

References (21)

1. Bleyer AM, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999; 33: 694-701.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607-617.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
4. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525.
5. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D. Cinacalcet HCI attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005; 67: 467-476.
6. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68: 1793-1800.
7. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int. 1992; 42: 1191-1198.
8. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soe Nephrol. 2001; 12: 2131-2138.
9. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
10. Lindberg JS, Culleton B, Wong G, Borah ME Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005; 16: 800-807.
11. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. 2003; Suppl: S111-114.
12. Martinez 1, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997; 29: 496-502.
13. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrot. 2004; 15: 2579-2587.
14. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Driieke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005; 67: 760-771.
15. National Kidney Foundation. K/DOQI Clinical Practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1-201.
16. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D. Pharmacodynamics of the Type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004; 308: 627-635.
17. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol. 2005; 16: 1788-1793.
18. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63: 1483-1490.
19. Waiters BAJ, Danese MD, Kim JJ, Klassen PS. Patient prevalence within proposed NKF-K/DOQI guidelines for bone metabolism and disease. J Am Soc Nephrol. 2003; 14: 473A (Abstract SA-PO799).
20. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44: 34-38.
21. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.